Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT06291987
Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation
- NCT06291987 ↗
- Recruiting
- University of Chicago
- Standard
We haven't built an HCP commentary report on NCT06291987 (ivosidenib plus ruxolitinib in IDH1-mutated advanced-phase myeloproliferative neoplasms) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT06291987 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| Bluesky threads | 19 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1b Trial of Ivosidenib Combined With Ruxolitinib in IDH1-Mutated Advanced-Phase MPNs
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Myeloproliferative Neoplasms
- Interventions
- Ivosidenib; Ruxolitinib
- Arms
- Dose Level -1 · Experimental
- Dose Level 1 · Experimental
- Dose Level 2 · Experimental
- Enrollment
- 18 (estimated)
- Primary outcomes
- Maximum tolerated dose
- Sponsor
- University of Chicago
- Start
- Sep 19, 2024
- Primary completion
- May 2029 (estimated)
- Results posted
- No
- Registry record
- NCT06291987 · updated Sep 1, 2026